Published in
Taylor and Francis Group, OncoImmunology, 1(9), 2020
DOI: 10.1080/2162402x.2020.1847846
Links
Tools
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Journal article published in 2020 by
Neeta Somaiah,
Sant P. Chawla,
Matthew S. Block,
John C. Morris,
Khanh Do,
Joseph W. Kim 
,
Mihaela Druta,
Kamalesh K. Sankhala,
Patrick Hwu,
Robin L. Jones,
Sacha Gnjatic,
Seunghee Kim-Schulze,
Kevin Tuballes,
Mahlet Yishak,
Hailing Lu
and other authors.
,
Mihaela Druta,
Kamalesh K. Sankhala,
Patrick Hwu,
Robin L. Jones,
Sacha Gnjatic,
Seunghee Kim-Schulze,
Kevin Tuballes,
Mahlet Yishak,
Hailing Lu
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 